Mariela Gunn
Office: PAR 102
Hours: M 4-5 & Th 10-12
+ individual appointments
Presymptomatic Testing
(In response to both articles)
In recent years, the possibility and sensitivity of genetic screening have increased dramatically by technological advances introduced by top researchers and scientists. Such technology includes the Genelex’s GeneMedRx drug-interaction test, a new service in which one can “customize” his/her combination of medication according to his/her genetic makeup. Another new tool is the HIV test that promises not only portability but also faster result, features that current HIV testing lacks. Currently, biotech companies are applying similar technology for screenings of heart diseases, cancer, and other diseases.
But imagine, what if we can detect these diseases before we can observe or experience any actual symptom? What if one’s genetic predispositions for diseases such as diabetes and cancer can be determined just by a simple blood test? Or better yet, what if we can use this knowledge of our genetic makeup and overcome our likelihood of getting a disease through technology and science?
These are just some of the ideals that many scientist and researchers are working toward in the next generation of genetic screening – presymptomatic testing. The concepts and technologies behind the HIV and drug-interaction testing are just the beginning of this new phenomenon. Promises of presymptomatic testing include the possibility of increasing longevity and reducing cost and time. But despite the benefits, I believe that many issues will certainly arise from the new information presented by presymptomatic testing and have a profound impact on the population.
The first issue that I would like to emphasize is the likely formation of new group and individual identities and practices arising out of this new knowledge. There already are, for example, breast cancer groups (e.g., Breast Cancer Support Group, Cochrane Breast Cancer Group) whose members meet to share their experiences, lobby for their disease, educate their children, and so on. So how likely is it to have groups forming according to one’s genetic makeup? Very likely. It is not hard to imagine groups formed around the chromosome 1, locus 123456, with a mutation on site 78901. Similar to the current breast cancer groups mentioned above, such groups will have medical specialists, narratives and other resources to help them experience, share, and understand their “fate”. Moreover, knowing one’s genetic profile will result in a constant drive to intervene with one’s “fate” through behavior modifications, therapy and such. People will be persistently monitoring and fixing their deviations.
The second issue that I would like to point out is that with the formation of new groups, classification will certainly arise. Although cultural classification such as race, gender, and age will not disappear, the meanings and the practices that constitute them certainly will change with the knowledge of individual’s genetic makeup. In the future, will we redefine the meaning of race by examining one’s genetic makeup instead of one’s skin color?
This brings me to my last point that by having our biological information revealed, the likelihood of genetic discrimination will be greatly increased (www.genome.gov/11510227). Insurance companies can use the information against participants by denying or limiting their health insurance because of their sensitivity to certain diseases. Discrimination can also occur if employers obtain individuals’ biological information and hire only workers with the best health prognoses.
Now, I am certainly not trying to denounce the practice of genetic screening, just that there are many issues that we should all think about.
